> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# BlackRock Crosses 5% Of Monopar Therapeutics With A 338,133-Share Stake
- URL: https://www.bullished.co/blackrock-crosses-5-of-monopar-therapeutics-with-a-338-133-share-stake-acc79346/
- Published: 2026-10-27T21:42:35.000Z
- Updated: 2026-11-05T20:02:16.000Z
- Description: The asset manager's passive filing shows sole voting power over 330,149 shares of the cancer and Wilson disease drug developer.
- Author: Matteo Parrino
- Tags: SEC Filings, MNPR, Industry: Healthcare

BlackRock now owns [5.03% of Monopar Therapeutics](https://www.sec.gov/Archives/edgar/data/0002012383/000201238326003819/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co), or 338,133 shares, according to a passive ownership filing (a Schedule 13G) made Tuesday. Monopar is a clinical-stage biopharmaceutical company, meaning its medicines are still in testing.

## Sole voting power over 330,149 shares

BlackRock reported sole voting power over 330,149 of the shares and no shared voting power. It filed as a parent holding company, with September 30, 2026 listed as the event date.

The 5.03% uses the filing's cover-page basis, which counts shares the holder could acquire within 60 days in both its holding and the share base.

BlackRock certified the shares were acquired and are held in the ordinary course of business, not to change or influence control of Monopar. The filing says various persons have the right to receive dividends or sale proceeds, and no one person's interest is more than 5%.

## Five BlackRock units behind the stake

An [exhibit](https://www.sec.gov/Archives/edgar/data/2012383/000201238326003819/Item%5F7.txt?ref=bullished.co) lists five BlackRock units as reporting entities: BlackRock Advisors, LLC; BlackRock Fund Advisors; BlackRock Institutional Trust Company, National Association; BlackRock Financial Management, Inc.; and BlackRock Investment Management, LLC.

## A Wilson disease and radiopharmaceutical developer

Monopar is developing ALXN1840, a once-daily oral medicine for Wilson disease, a rare genetic condition in which the body cannot clear excess copper. It holds an exclusive worldwide license to the drug from Alexion, according to its annual report, and expects to submit a marketing application to the FDA in mid-2026.

It also develops cancer radiopharmaceuticals built on MNPR-101, an antibody that targets a protein called uPAR found on many tumors. Phase 1 trials of MNPR-101-Zr, for imaging, and MNPR-101-Lu, for treatment, are enrolling patients in Australia.

Monopar's market value was $473 million in Tuesday trading.

The filing's cover page puts BlackRock's holding at 338,133 shares, with 330,149 of them carrying sole voting power.

Learn

- [What a Reverse Termination Fee Means: Who Pays When a Merger Collapses →](https://www.bullished.co/learn/reverse-termination-fee-meaning/)  
A reverse termination fee is paid by the buyer to the target if a merger fails on agreed terms. See how it differs from a break-up fee, with live deal examples.
- [How To Read A Merger Proxy: A Checklist For Shareholders Facing A Vote →](https://www.bullished.co/learn/merger-proxy-statement-how-to-read/)  
Facing a merger vote? Read the proxy in this order: price and payment, vote date and threshold, board background, synergy claims, then closing conditions.

### Sources

- [SCHEDULE 13G — BlackRock, Inc. re: MONOPAR THERAPEUTICS (MNPR)](https://www.sec.gov/Archives/edgar/data/0002012383/000201238326003819/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR
- [SCHEDULE 13G Exhibit 99 — EXHIBIT 99: ITEM 7](https://www.sec.gov/Archives/edgar/data/2012383/000201238326003819/Item%5F7.txt?ref=bullished.co) — SEC EDGAR
- [Analysts Are Bullish on Top Healthcare Stocks: Perspective Therapeutics (CATX), Oric Pharmaceuticals (ORIC) - The Globe and Mail](https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/8470280/analysts-are-bullish-on-top-healthcare-stocks-perspective-therapeutics-catx-oric-pharmaceuticals-oric/?ref=bullished.co) — theglobeandmail.com